Global Defense Contractor Burke Products Selects Datavault AI for Enhanced National Defense and Aerospace Technologies Contracts
Within the partnership Datavault AI has been contracted by Burke Products to engineer and produce solutions responsive to an array of opportunities. All opportunities are managed under the contract in a case by case fashion designed to be responsive to private and public RFPs and requests made directly and through subcontracts obtained by Burke and other contracting mechanisms in place at Burke Products on a global basis.
Military grade engineering, manufacturing and productization is now underway. The collaboration aims to advance defense and aerospace capabilities by integrating Datavault AI's services and proprietary data and ADIO® tone technologies with Burke's experienced manufacturing and engineering teams to accelerate productization and speed to market that Datavault AI's technologies have been designed to automate and support at scale.
According to Janes, global defense spending is projected to exceed $2.2 trillion in 2025, with the U.S. defense budget alone expected to surpass $900 billion. As modernization efforts escalate, the sector is increasingly focused on secure data solutions, advanced tracking, and predictive intelligence—areas where Datavault AI is uniquely positioned to deliver for Burke new and innovative solutions that solve for advantages and forward progression of technologies in this sector. With Web 3.0 centric contributions of Datavault AI this partnership will explore technological synergies with particular emphasis on secure data management, resource tracking, and communication systems critical to mission success.
Aaron Bakhshi, CEO of Burke Products, shared his outlook on the business alliance and licensing contracts now in place with Datavault AI, 'For more than 59 years, Burke Products has supplied advanced electro-mechanical components and assemblies to leading defense and aerospace partners, including Lockheed Martin, Raytheon Technologies, Northrop Grumman, General Dynamics, the U.S. Navy, the Defense Logistics Agency, and their allied international counterparts. As a minority-owned defense contractor committed to engineering innovation, we view this strategic alliance with Datavault AI as a transformative step toward future-ready solutions. The introduction and demonstrations of Datavault's solutions into our product portfolio marks a significant evolution in how we approach innovation across mission-critical systems.'
Bakhshi continued: 'This collaboration originated from Sonia Choi's ability to identify and align mutual strategic interests, particularly around innovations in acoustic sciences and separately, the urgent challenge of addressing stolen valor—two distinct areas where Datavault AI's platform provides an elegant and effective solution. Additionally, our shared vision around the scalable deployment of Digital Twin technologies further strengthens the foundation of this partnership and unlocks significant future potential. Her skill in connecting advanced technology to real-world defense applications and viable business models was instrumental in forming this agreement. It resonates with me, as it reflects the executive vision and innovation that Burke Products strives to champion across all of our initiatives. We believe the work underway with Datavault AI will deliver measurable value to our clients and help redefine operational standards across multiple defense verticals with new Web 3.0 solutions.'
The first phase will integrate Datavault AI's acoustic sciences services and products, including patented ADIO® tone technology, into Burke's pre-existing systems. Future phases may expand into integrating Datavault AI's proprietary data solutions for digital twin modeling, predictive analytics, inventory logistics and management as well as blockchain-based tools to secure supply chains and authenticate critical components throughout their lifecycle.
'It has been an honor to work with and partner alongside Aaron Bakhshi and Burke Products to help extend Datavault AI's orchestrated blend of talent and technological footprint into the defense sector,' said Sonia Choi, Co-Founder and CMO of Datavault AI and Lead Principal Investigator on a privately funded Strategic Partnership Project facilitated through the U.S. Department of Energy's Brookhaven National Laboratory.
'Burke Products has a rare and profound legacy of combining engineering precision with innovation—qualities that immediately resonated with our shared commitment to mission-critical performance. We are both builders and systems thinkers, capable of harnessing our technologies to automate high-value solutions in environments defined by complexity and zero tolerance for error. By leveraging our advanced data and acoustic sciences to solve real-world problems and by aligning our ecosystems together, we're laying the groundwork for scalable, American-built solutions. This marks a pivotal step and underscores Datavault AI's strategic entry into, and sustained relevance within, modern defense infrastructure,' stated Sonia Choi.
As the defense and aerospace sectors rapidly evolve, this partnership marks a significant milestone. With a focus on security, precision, and next-gen data integration, Datavault AI and Burke Products are working together to shape the future of national defense technology.
Nathaniel T. Bradley, Co-Founder and CEO of Datavault AI, asserted: ' This collaboration marks an international milestone of a scale we couldn't have anticipated when we first founded the company. Sonia Choi has been diligently building toward this moment for years, and her ability to identify high-impact applications for Datavault AI's technologies—while guiding our team through the execution with focus and discipline—has been exceptional. Through her vision and leadership, we've reached a breakthrough that aligns seamlessly across our VerifyU, ADIO®, High Performance Computing, WiSA and Datavault platforms, in concert with Burke Products' expansive capabilities, trusted network, and precision-driven engineering excellence.'
Bradley noted, 'Together, with Burke Products, we now have an industry leading, solutions-oriented contracting partner that not only understands Datavault AI's mission, but is equipped to deliver defense-grade, purpose-built innovations when they are most needed. Sonia's and Aaron's influence will have a lasting impact—not only on Datavault AI's trajectory, but on the broader U.S. defense industry it serves. We're deeply grateful to Burke Products for validating our intellectual property, recognizing the strength of our team, and stepping forward with us to realize the full potential of this partnership.'
About Datavault AI Inc.
Datavault AI TM (Nasdaq: DVLT) is leading the way in AI driven data experiences, valuation and monetization of assets in the Web 3.0 environment. The company's cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Science and Data Science Divisions. Datavault AI's Acoustic Science Division features WiSA®, ADIO® and Sumerian® patented technologies and industry-first foundational spatial and multichannel wireless HD sound transmission technologies with IP covering audio timing, synchronization and multi-channel interference cancellation. The Data Science Division leverages the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation and secure monetization. Datavault AI's cloud-based platform provides comprehensive solutions serving multiple industries, including HPC software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The Information Data Exchange® (IDE) enables Digital Twins, licensing of name, image and likeness (NIL) by securely attaching physical real-world objects to immutable metadata objects, fostering responsible AI with integrity. Datavault AI's technology suite is completely customizable and offers AI and Machine Learning (ML) automation, third-party integration, detailed analytics and data, marketing automation and advertising monitoring. The company is headquartered in Beaverton, OR. Learn more about Datavault AI at www.dvlt.ai.
About Burke Products, Inc.
Burke Products, Inc. is a minority-owned manufacturer of high-precision electro-mechanical components and assemblies, serving the aerospace and defense sectors for over 59 years. The company has established a longstanding reputation for reliability and excellence across critical supply chains, maintaining established relationships with clients including the U.S. Department of Defense, Defense Logistics Agency (DLA), Lockheed Martin, Raytheon Technologies, Honeywell, General Dynamics, Goodrich, and Johnson & Johnson. Internationally, Burke has fulfilled government contracts and procurement programs for India and our allied defense partners in the UK, Japan, Germany, Turkey, and many others. Operating under ISO and AS-compliant quality systems, Burke specializes in contracted manufacturing, acoustic systems and technology integration, and rapid design-to-production capabilities for defense-grade hardware. Its core competencies support both domestic and allied military readiness through scalable, high-integrity supply partnerships.
To learn more about Burke Products, please visit https://burkeproducts.com/.
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other securities laws. Words such as "expect," "will," "anticipates," "estimates" and variations of such words and similar future or conditional expressions are intended to identify forward-looking statements. Such forward-looking statements, including statements herein regarding our business opportunities and prospects, strategy, future revenue expectations, licensing initiatives, recent funding and M&A activities as well as our plans to integrate acquired businesses and technologies, are necessarily based upon estimates and assumptions that, while considered reasonable by us and our management, are inherently uncertain. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various risks and uncertainties including, but not limited to, the following: the risk that we are unable to satisfy all closing conditions in connection with the senior notes issuance described above, and the acquisition of certain assets from CSI; our ability to successfully integrate all IP that we have acquired; risks regarding our ability to utilize the assets we acquire to successfully grow our market share; risks regarding our ability to open up new revenue streams as a result of the various agreements we have entered into and assets we have acquired; our current liquidity position and the need to obtain additional financing to support ongoing operations; general market, economic and other conditions; our ability to continue as a going concern; our ability to maintain the listing of our common stock on Nasdaq; our ability to manage costs and execute on our operational and budget plans; our ability to achieve our financial goals; the degree to which our licensees implement the licensed technology into their products, if at all; the timeline to any such implementation; risks related to technology innovation and intellectual property, and other risks as more fully described in our filings with the U.S. Securities and Exchange Commission. The information in this press release is provided only as of the date of this press release, and we undertake no obligation to update any forward-looking statements contained in this communication based on new information, future events, or otherwise, except as required by law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
12 minutes ago
- Globe and Mail
CareTrust REIT, Inc. Announces Pricing of Upsized Public Offering of Common Stock
CareTrust REIT, Inc. (NYSE: CTRE) ('CareTrust REIT' or the 'Company') announced the pricing of its upsized underwritten public offering of 20,000,000 shares of common stock at a price to the public of $32.00 per share. The offering is expected to close on August 14, 2025, subject to customary closing conditions. In connection with the offering, the Company has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of common stock. The Company intends to contribute the net proceeds to CTR Partnership, L.P., its operating partnership, which will in turn use the proceeds from this offering to fund new investments and repay the borrowings outstanding on its revolving credit facility. J.P. Morgan, BofA Securities and RBC Capital Markets are acting as joint lead book-running managers for the offering. BMO Capital Markets, KeyBanc Capital Markets, Morgan Stanley and Wells Fargo Securities are also acting as joint book-running managers for the offering. Huntington Capital Markets, M&T Securities and Raymond James are acting as co-managers for the offering. A shelf registration statement (including prospectus) relating to the Company's common stock was previously filed with the Securities and Exchange Commission (the 'SEC') and was automatically effective upon filing. This offering may only be made by means of a prospectus supplement and the accompanying prospectus. A copy of the preliminary prospectus supplement relating to this offering was filed with the SEC on August 12, 2025, and a final prospectus supplement relating to the offering will be filed with the SEC. A copy of the final prospectus supplement, when available, and accompanying prospectus relating to the offering may be obtained from J.P. Morgan Securities LLC, c/o: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at prospectus-eq_fi@ and postsalemanualrequests@ BofA Securities, Inc., Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255-0001, or by email at or RBC Capital Markets, LLC, 200 Vesey Street, 8th Floor, New York, NY 10281-8098, Attention: Equity Syndicate, by telephone at 877-822-4089, or by email at equityprospectus@ You may also obtain a copy of the preliminary prospectus supplement and accompanying prospectus and, when available, the final prospectus supplement and accompanying prospectus, without charge, by visiting the SEC's website at This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any offer, solicitation or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About CareTrust REIT™ CareTrust REIT, Inc. is a self-administered, publicly-traded real estate investment trust engaged in the ownership, acquisition, development and leasing of skilled nursing, seniors housing and other healthcare-related properties. With a portfolio of long-term net-leased properties spanning the United States and United Kingdom, and a growing portfolio of quality operators leasing them, CareTrust is pursuing both external and organic growth opportunities across the US and internationally.
Globe and Mail
42 minutes ago
- Globe and Mail
Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering
BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. ('Compass') (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the pricing of an underwritten public offering of 33,290,000 shares of its common stock at a price to the public of $3.00 per share and pre-funded warrants to purchase up to an aggregate of 6,710,000 shares of its common stock at a price to the public of $2.9999 per pre-funded warrant to purchase one share of the common stock, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant. The gross proceeds from the offering to Compass are expected to be approximately $120 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about August 14, 2025, subject to customary closing conditions. In addition, Compass has granted the underwriters a 30-day option to purchase up to 6,000,000 additional shares of common stock at the public offering price, less the underwriting discount. Compass intends to use the net proceeds from the offering to conduct initial preparations for commercial readiness, to fund research and clinical development of its product candidates, and for general corporate purposes. Jefferies, Piper Sandler and Guggenheim Securities are acting as joint active bookrunning managers for the offering. Raymond James, Wedbush PacGrow and H.C. Wainwright & Co. are acting as lead managers for the offering. Ladenburg Thalmann and D. Boral Capital are acting as co-managers for the offering. A shelf registration statement on Form S-3 relating to the securities offered in the public offering described above was filed with the Securities and Exchange Commission (the 'SEC') on August 30, 2024 and declared effective by the SEC on September 6, 2024. The offering will be made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and is available on the SEC's website at A final prospectus supplement and accompanying prospectus will be filed with the SEC. Copies of the final prospectus supplement and the accompanying prospectus, when available, may also be obtained by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@ Piper Sandler & Co. by mail at 350 North 5 th Street, Suite 1000, Minneapolis, Minnesota 55401 or by email at prospectus@ and Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8 th Floor, New York, NY 10017, telephone: (212) 518-9544, email: GSEquityProspectusDelivery@ This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Compass Therapeutics Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass has built a robust pipeline of novel product candidates designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. The company plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. Forward-Looking Statements Various statements in this release concerning the timing and completion of the public offering on the anticipated terms or at all may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of substantial risks and uncertainties, many of which are outside Compass's control, that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include fluctuations in Compass's stock price, changes in market conditions, the final terms of the public offering and satisfaction of customary closing conditions related to the public offering, as well as those risks more fully discussed in the section entitled 'Risk Factors' in the prospectus supplement and registration statement referenced above and in Compass's Annual Report on Form 10-K for the year ended December 31, 2024, filed on February 27, 2025 with the SEC and subsequent reports with the SEC. There can be no assurance that Compass will be able to complete the public offering on the anticipated terms. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Compass undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law.
CBC
2 hours ago
- CBC
Alberta canola farmer tired of taking one for the team in China tariff dispute
The Canadian Canola Growers Association says China's plans to impose a new duty on Canadian canola on Aug. 14 will effectively lock the industry out of one of its biggest trading partners. This is the latest escalation in the trade dispute with China that began with Canadian tariffs on Chinese electric vehicle imports last year.
